Showing results (121-130 of 153) with videos related to
Sort By:
Pageof 16
The Lancet. Oncology|April 11, 2022
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trialUlrike Nitz, Oleg Gluz, Monika Graeser, et al.JAMA Oncology|May 11, 2023
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical TrialOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 TrialMonika Graeser, Oleg Gluz, Peter Schmid, et al.Oncogene|April 19, 2022
Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancerMax A K Rätze, Thijs Koorman, Thijmen Sijnesael, et al.NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.Breast Cancer Research : BCR|January 25, 2025
Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markersLothar Häberle, Ramona Erber, Paul Gass, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology AssessmentOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.Journal for Immunotherapy of Cancer|May 8, 2021
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trialMonika Graeser, Friedrich Feuerhake, Oleg Gluz, et al.NPJ Breast Cancer|March 21, 2024
Reporting on invasive lobular breast cancer in clinical trials: a systematic reviewKaren Van Baelen, Josephine Van Cauwenberge, Marion Maetens, et al.Breast Care (Basel, Switzerland)|March 16, 2026
Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPTMichael Braun, Oleg Gluz, Sherko Kuemmel, et al.Pageof 16